SANUWAVE Health Announces Preliminary Revenue Results for the First Quarter 2025 (Ended March 31, 2025)
MWN-AI** Summary
SANUWAVE Health, Inc. (NASDAQ: SNWV) has announced impressive preliminary revenue results for the first quarter of 2025, reporting revenues between $9.1 million and $9.3 million. This achievement marks the highest first-quarter revenue in the company's history, reflecting a substantial increase of 57% to 61% compared to the same period in 2024. The significant surge can be primarily attributed to UltraMIST revenues, which saw a remarkable rise of over 65% year-over-year, representing nearly 99% of the company's total revenue for the quarter.
Chief Executive Officer Morgan Frank expressed pride in the team’s performance amidst a transition period marked by a new head of sales and a restructuring of the sales force. Despite these changes, the company did not miss any operational milestones, showcasing strong adaptability. Frank further highlighted the robustness of SANUWAVE's pipeline, indicating optimism for 2025 as a potential breakout year for the company.
SANUWAVE plans to release the comprehensive financial results for Q1 2025 on or around May 9, 2025. In light of current economic conditions, including trade tariffs, Frank clarified that all manufacturing for the UltraMIST system occurs domestically, with no expected disruptions to production levels.
The company is focused on innovating non-invasive medical systems aimed at enhancing wound care and tissue regeneration, thus positioning itself as a leader in the healthcare market. However, investors are reminded that forward-looking statements may carry inherent uncertainties and are not guarantees of future performance, as many factors could influence actual results. The preliminary revenue figures remain subject to adjustment upon concluding the quarter-end financial review.
MWN-AI** Analysis
SANUWAVE Health, Inc. (NASDAQ: SNWV) has reported preliminary revenues for Q1 2025 ranging from $9.1 million to $9.3 million, marking the strongest Q1 in the company's history and a notable increase of 57% to 61% year-over-year. A significant contributor to this growth was the UltraMIST device, which alone accounted for approximately 99% of total sales, witnessing over a 65% rise from Q1 2024. The company’s strategic restructuring of its sales team and leadership under CEO Morgan Frank has clearly yielded positive short-term results.
Investors should take heed of several market implications from these results. First, SANUWAVE’s reliance on the UltraMIST product, while currently a strong performer, poses risks related to product concentration. Thus, monitoring diversification efforts and new product introductions will be critical for long-term growth sustainability. Additionally, the domestic manufacturing of UltraMIST, particularly in the light of ongoing tariff concerns, suggests reduced risk exposure compared to competitors who might rely on international production.
The sentiment around SANUWAVE appears optimistic, bolstered by the CEO's assertion of a robust pipeline and expectations for a "breakout year." However, potential investors should remain cautious over the upcoming full quarterly results due on May 9, 2025, which might adjust the market's current expectations and should reflect actual performance compared to the forecasts.
For existing shareholders, this upward trajectory could warrant holding or even increasing positions, provided that growth is matched by prudent management of operational risks. For potential investors, an entry might be considered post the Q1 results release, evaluating the overall health of the company's financials and its strategic positioning in the highly competitive wound care market.
In summary, while SANUWAVE's preliminary results are promising, vigilance regarding its revenue resilience, product diversification, and financial health will be essential going forward.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
SANUWAVE is pleased to announce preliminary revenues of $9.1 million to $9.3 million for the first quarter ended March 31, 2025. This represents the highest Q1 quarterly revenues in Company history.
Q1 2025 revenue increased between 57% and 61% compared to Q1 2024.
UltraMIST revenues for Q1 2025 increased by more than 65% versus Q1 2024 and accounted for approximately 99% of the Company’s total revenues.
EDEN PRAIRIE, Minn., April 08, 2025 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, today announced that revenues for the first quarter of 2025 are expected to be in the range of $9.1 to $9.3 million, an increase of 57% to 61% over Q1 2024 and slightly above the upper end of the range of guidance given in the Company’s Q4 2024 earnings release issued on March 21, 2025.
“Sanuwave is pleased to announce a strong start to 2025, putting up our best Q1 in Company history,” said CEO Morgan Frank. “Q1 was a transition quarter as we moved to a new head of sales and restructured the sales force. I’m very proud of the team managing this without missing a beat. Our pipeline remains robust and consistent with 2025 being a breakout year for Sanuwave. The Company plans to release its full Q1 results on or around May 9, 2025 and we look forward to speaking with you then to give you a more complete update on our quarterly performance and our future plans and guidance.”
“Given the current trade climate and as we have received a number of questions from investors, I’d also like to take this opportunity to clarify that all manufacturing for the UltraMIST system and its applicators is performed domestically. Sanuwave does not anticipate any significant effects on production from the current tariff situation.”
The preliminary revenue results described herein are based on management’s initial analysis of the first quarter ended March 31, 2025, and may be subject to adjustments based on the Company’s completion of its quarter-end financial close process.
About SANUWAVE
SANUWAVE Health is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.
SANUWAVE’s end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body’s normal healing processes. SANUWAVE applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectations, plans for future business development activities and expectations regarding the impact of changes in tariff rates. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with regulatory oversight, the Company’s ability to manage its capital resources, competition and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
Contact: investors@sanuwave.com
FAQ**
Given the significant revenue growth reported, what specific strategies has Sanuwave Health Inc SNWV implemented to achieve the 57% to 6increase in Q1 2025 revenues compared to Q1 2024?
How does Sanuwave Health Inc SNWV plan to leverage the robust pipeline mentioned by CEO Morgan Frank to sustain growth throughout 20and beyond?
Can you elaborate on how Sanuwave Health Inc SNWV's transition to a new head of sales and restructured sales force impacted the company’s revenue performance in Q1 2025?
What measures is Sanuwave Health Inc SNWV taking to address potential risks associated with regulatory oversight and competition as mentioned in the forward-looking statements?
**MWN-AI FAQ is based on asking OpenAI questions about SANUWAVE Health Inc. (NASDAQ: SNWV).
NASDAQ: SNWV
SNWV Trading
-11.01% G/L:
$17.21 Last:
64,631 Volume:
$18.94 Open:
